Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.6190
+0.0093 (1.53%)
At close: Jun 5, 2026, 4:00 PM EDT
0.5804
-0.0386 (-6.24%)
After-hours: Jun 5, 2026, 7:25 PM EDT
Evogene Employees
Evogene had 52 employees as of December 31, 2025. The number of employees decreased by 65 or -55.56% compared to the previous year.
Employees
52
Change (1Y)
-65
Growth (1Y)
-55.56%
Revenue / Employee
$35,462
Profits / Employee
-$226,308
Market Cap
6.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 52 | -65 | -55.56% | 52 | 0 |
| Dec 31, 2024 | 117 | -25 | -17.61% | 117 | 0 |
| Dec 31, 2023 | 142 | 5 | 3.65% | 142 | 0 |
| Dec 31, 2022 | 137 | -4 | -2.84% | 137 | 0 |
| Dec 31, 2021 | 141 | 10 | 7.63% | 141 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 33 |
| Cardio Diagnostics Holdings | 17 |
| FibroBiologics | 15 |
| Processa Pharmaceuticals | 12 |
| Purple Biotech | 10 |
| Enveric Biosciences | 6 |
| Can-Fite BioPharma | 5 |
| Silo Pharma | 3 |
EVGN News
- 5 days ago - Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results - GuruFocus
- 5 days ago - Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TheFly
- 5 days ago - Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PRNewsWire
- 12 days ago - Evogene price target lowered to $2.15 from $2.25 at Alliance Global - TheFly
- 18 days ago - Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet
- 18 days ago - Evogene Earnings Call Transcript: Q1 2026 - Transcripts
- 18 days ago - Evogene Earnings release: Q1 2026 - Filings
- 18 days ago - Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation - GuruFocus